Showing results (11-20 of 439) with videos related to
Sort By:
Pageof 44
Leukemia Research|March 25, 2009
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolismMassimo Breccia, Giuliana AlimenaExpert Opinion on Investigational Drugs|January 21, 2026
ADVANCES OF NEXT-GENERATION STAMP INHIBITORS IN CHRONIC MYELOID LEUKEMIAAlessandro Costa, Massimo BrecciaMediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIsMassimo Breccia, Giuliana AlimenaClinical Lymphoma, Myeloma & Leukemia|April 27, 2025
SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic StrategiesAlessandro Costa, Massimo BrecciaClinical Lymphoma, Myeloma & Leukemia|April 6, 2025
SOHO State of the Art Updates and Next Questions | Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges and Therapeutic StrategiesAlessandro Costa, Massimo BrecciaExpert Opinion on Therapeutic Targets|September 23, 2010
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemiaMassimo Breccia, Giuliana AlimenaCancer Letters|March 28, 2012
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantagesMassimo Breccia, Giuliana AlimenaRare Cancers and Therapy|May 17, 2016
Bosutinib for Chronic Myeloid LeukemiaMassimo Breccia, Gianni BinottoAnnals of Hematology|February 19, 2013
Efficacy and safety of deferasirox in myelodysplastic syndromesMassimo Breccia, Giuliana AlimenaLeukemia Research|March 12, 2013
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitorsMassimo Breccia, Giuliana AlimenaPageof 44